Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 4/20 | 0.50 |
| ▸ | IDO1 | P14902 | 2/20 | 0.48 |
| ▸ | AGXT | P21549 | 2/20 | 0.48 |
| ▸ | MAOB | P27338 | 1/20 | 0.46 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2185725 | 0.94 | SIGMAR1 (0.49) | TAAR1IDO1AGXTMAOBSIGMAR1 | |
| SCHEMBL13335507 | 0.94 | SIGMAR1 (0.49) | TAAR1IDO1AGXTMAOBSIGMAR1 | |
| SCHEMBL2187692 | 0.94 | SIGMAR1 (0.49) | TAAR1IDO1AGXTMAOBSIGMAR1 | |
| SCHEMBL16238296 | 0.90 | TAAR1 (0.46) | TAAR1IDO1AGXTMAOBSIGMAR1 | |
| SCHEMBL237706 | 0.88 | TAAR1 (0.44) | TAAR1IDO1AGXTMAOBSIGMAR1 | |
| SCHEMBL7852354 | 0.88 | TAAR1 (0.53) | TAAR1IDO1AGXTMAOBSIGMAR1 | |
| SCHEMBL3416256 | 0.87 | TAAR1 (0.50) | TAAR1IDO1AGXTMAOBSIGMAR1 | |
| SCHEMBL14402629 | 0.85 | CYP1A2 (0.46) | TAAR1IDO1AGXTSIGMAR1CYP1A2 | |
| SCHEMBL13849897 | 0.85 | CYP1A2 (0.46) | TAAR1IDO1AGXTSIGMAR1CYP1A2 | |
| SCHEMBL22607932 | 0.84 | FOLH1 (0.45) | SIGMAR1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025108255-A1 | POLYCYCLIC DERIVATIVE, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 上海齐鲁制药研究中心有限公司 | 2025-05-30 | — | — | WO | disclosed |
| EP-1768989-B1 | METAL COMPLEXES | MERCK PATENT GMBH (DE) | 2011-11-23 | — | — | EP | disclosed |
| EP-1768989-B1 | METAL COMPLEXES | MERCK PATENT GMBH (DE) | 2011-11-23 | — | — | EP | disclosed |
| US-7816531-B2 | Metal complexes | MERCK PATENT GMBH (DE) | 2010-10-19 | — | — | US | disclosed |
| US-7816531-B2 | Metal complexes | MERCK PATENT GMBH (DE) | 2010-10-19 | — | — | US | disclosed |
| US-7816531-B2 | Metal complexes | MERCK PATENT GMBH (DE) | 2010-10-19 | — | — | US | disclosed |
| US-20080027220-A1 | Metal Complexes | MERCK PATENT GMBH (DE) | 2008-01-31 | — | — | US | disclosed |
| US-20080027220-A1 | Metal Complexes | MERCK PATENT GMBH (DE) | 2008-01-31 | — | — | US | disclosed |
| US-20080027220-A1 | Metal Complexes | MERCK PATENT GMBH (DE) | 2008-01-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080027220-A1 | Metal Complexes | AP1M1, SOD1, AP1G1 | TAAR1 1616/4885IDO1 915/4885AGXT 2846/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.